Therapeutic modulators of STAT signalling for human diseases

Related Experiment Video

Updated: May 9, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Gabriella Miklossy1, Tyvette S Hilliard, James Turkson

  • 1Cancer Biology, and Natural Products and Experimental Therapeutics Programs, University of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, Hawaii 96813, USA.

Nature Reviews. Drug Discovery
|August 2, 2013
PubMed

Insights

Drug discovery efforts targeting signal transducer and activator of transcription (STAT) proteins continue, with ongoing research into modulators for various diseases. This review highlights successful clinical trial candidates and future directions for STAT-targeted therapeutics.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Biochemistry

Background:

  • Signal transducer and activator of transcription (STAT) proteins regulate critical biological processes.
  • Aberrant STAT signaling is linked to numerous diseases, including cancer, autoimmune disorders, and diabetes.
  • Developing STAT protein inhibitors has been an active area of research for over a decade.

Purpose of the Study:

  • To review the progress of drug discovery research targeting STAT proteins.
  • To provide insights into novel strategies for accelerating the development of STAT-targeting drugs.
  • To highlight promising therapeutic candidates that have advanced into clinical trials.

Main Methods:

  • Literature review of drug discovery research on STAT proteins.
  • Analysis of outcomes from ongoing research endeavors.
  • Identification and summary of STAT-targeting drug candidates in clinical development.

Main Results:

  • Significant research efforts have been dedicated to discovering STAT protein modulators.
  • Several therapeutic candidates targeting STAT signaling pathways have progressed to clinical trials.
  • The review synthesizes current findings and identifies key areas for future research.

Conclusions:

  • Continued investigation into STAT protein modulators holds therapeutic potential for various diseases.
  • Accelerated drug discovery strategies are needed to advance novel STAT-targeting agents.
  • Clinical trial progress indicates the viability of STAT-targeted therapies.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...